AlphaCrest Capital Management LLC cut its position in Quest Diagnostics Incorporated (NYSE:DGX – Get Rating) by 42.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,290 shares of the medical research company’s stock after selling 9,796 shares during the period. AlphaCrest Capital Management LLC’s holdings in Quest Diagnostics were worth $1,767,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in DGX. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Quest Diagnostics by 5.8% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 11,867 shares of the medical research company’s stock worth $1,624,000 after acquiring an additional 654 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Quest Diagnostics in the first quarter worth $524,000. NorthCrest Asset Manangement LLC grew its holdings in shares of Quest Diagnostics by 515.2% during the second quarter. NorthCrest Asset Manangement LLC now owns 16,013 shares of the medical research company’s stock worth $2,129,000 after purchasing an additional 13,410 shares during the last quarter. Kentucky Retirement Systems increased its stake in shares of Quest Diagnostics by 14.8% in the second quarter. Kentucky Retirement Systems now owns 8,711 shares of the medical research company’s stock valued at $1,158,000 after buying an additional 1,126 shares in the last quarter. Finally, Argent Trust Co raised its holdings in shares of Quest Diagnostics by 1.4% in the first quarter. Argent Trust Co now owns 27,237 shares of the medical research company’s stock valued at $3,728,000 after buying an additional 374 shares during the last quarter. 88.87% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts have weighed in on the stock. William Blair restated an “outperform” rating on shares of Quest Diagnostics in a research report on Thursday, October 20th. Morgan Stanley raised their price target on shares of Quest Diagnostics from $142.00 to $146.00 and gave the company an “equal weight” rating in a report on Friday, October 21st. Citigroup lowered Quest Diagnostics from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $145.00 to $125.00 in a research report on Thursday, November 17th. StockNews.com downgraded Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 8th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Quest Diagnostics from $129.00 to $140.00 and gave the company a “hold” rating in a report on Friday, October 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $148.50.
Insider Transactions at Quest Diagnostics
Quest Diagnostics Stock Up 1.2 %
Shares of Quest Diagnostics stock opened at $148.46 on Thursday. The business has a fifty day simple moving average of $134.89 and a 200 day simple moving average of $134.74. The stock has a market cap of $16.91 billion, a PE ratio of 14.60 and a beta of 1.02. The company has a quick ratio of 1.34, a current ratio of 1.46 and a debt-to-equity ratio of 0.63. Quest Diagnostics Incorporated has a 12 month low of $120.40 and a 12 month high of $174.16.
Quest Diagnostics (NYSE:DGX – Get Rating) last posted its earnings results on Thursday, October 20th. The medical research company reported $2.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.17. The company had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.34 billion. Quest Diagnostics had a return on equity of 21.36% and a net margin of 12.00%. The company’s revenue for the quarter was down 10.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.96 EPS. Research analysts predict that Quest Diagnostics Incorporated will post 9.85 EPS for the current year.
Quest Diagnostics Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Shareholders of record on Wednesday, January 18th will be issued a $0.66 dividend. The ex-dividend date of this dividend is Tuesday, January 17th. This represents a $2.64 annualized dividend and a yield of 1.78%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 25.96%.
Quest Diagnostics Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
- Get a free copy of the StockNews.com research report on Quest Diagnostics (DGX)
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.